Breast Cancer Foundation NZ
EMT Study
Advanced Breast Cancer clinical trials for ER+
The EMT study is investigating a molecular process (epithelial-mesenchymal transition) which can occur in the breast cancer cells of some patients, which can make the cancer more aggressive and might reflect how well the cancer cells will respond to treatment.
It is hoped this research will provide more information regarding the EMT process which may allow doctors to better select treatment for their patients whose breast cancer has this feature, and potentially allow the development of new drugs which can target the EMT process to increase cancer cell kill.
Who is it for?
Eligible patients in this study are aged 18 years or older, have been diagnosed with HER+, HER2- breast cancer and have received a cyclin D kinase inhibitor in the adjuvant setting and have experienced a breast cancer recurrent event, or have received a cyclin D kinase inhibitor for treatment of advanced cancer. Any advanced breast cancer patient who has received at least one dose of eribulin in the course of their treatment may also be eligible.
Study details
All participants enrolled in this study will be asked to provide one to two tumour biopsies (tissue samples) that will be used to perform the molecular tests to determine EMT activity. Samples from previous surgeries and/or biopsies may be used to perform the molecular tests. Some eligible participants may be asked to undergo a maximum of two new biopsies if tissue from prior procedures is not available. No other patient procedures will be performed.
Australia
If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Advanced Breast Cancer
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.